TREACE MEDICAL CONCEPTS, INC.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

TMCI$4.88+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue	$47,387	$44,455	$99,957	$95,563
Cost of goods sold	9,635	8,781	20,312	18,908
Gross profit	37,752	35,674	79,645	76,655
Operating expenses
Sales and marketing	33,084	37,681	69,206	78,009
Research and development	5,498	5,157	11,060	10,416
General and administrative	16,144	14,218	31,935	28,580
Total operating expenses	54,726	57,056	112,201	117,005
Loss from operations	(16,974)	(21,382)	(32,556)	(40,350)
Interest income	775	1,376	1,616	2,911
Interest expense	(1,321)	(1,312)	(2,632)	(2,629)
Other income, net	122	112	252	186
Other non-operating income (expense), net	(424)	176	(764)	468
Net loss	$(17,398)	$(21,206)	$(33,320)	$(39,882)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities	(7)	(95)	(47)	(189)
Comprehensive loss	$(17,405)	$(21,301)	$(33,367)	$(40,071)
Net loss per share, basic and diluted	$(0.28)	$(0.34)	$(0.53)	$(0.64)
Weighted-average shares used in computing net loss per share, basic and diluted	63,006,891	62,081,494	62,843,337	61,937,140

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.